HEALTHJun 25 · 18:58 UTCSTAT NEWSElaine Chen and Allison DeAngelis

The mysterious case of Eli Lilly’s obesity drug

Eli Lilly's obesity drug retatrutide is being made available to one individual through the FDA's 'compassionate use' program. The article discusses this development alongside broader questions about drugmaker acquisitions and the investment potential of hair loss drugs, as covered in a podcast episode.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Eli LillyorganizationretatrutidetopicFood and Drug AdministrationorganizationLizzy LawrencepersonThe Readout LOUDorganizationcompassionate usetopichair loss drugstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 24 · 10:19 UTC
White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
HEALTHJun 23 · 08:30 UTC
STAT+: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?
HEALTHJun 6 · 18:32 UTC
STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
HEALTHMay 28 · 13:26 UTC
STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more